Steris (STE) International Revenue in Focus: Trends and Expectations

Zacks Equity Research

Mon, Feb 10, 2025, 7:15 AM 4 min read

Did you analyze how Steris (STE) fared in its international operations for the quarter ending December 2024? Given the widespread global presence of this medical products maker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.

In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.

Participation in global economies acts as a defense against economic difficulties at home and a pathway to more rapidly developing economies. However, it also comes with the complexities of dealing with fluctuating currencies, geopolitical risks and different market dynamics.

In our recent assessment of STE's quarterly performance, we discovered notable trends in its overseas revenue sections, which are typically modeled and scrutinized by Wall Street analysts.

The recent quarter saw the company's total revenue reaching $1.37 billion, marking a decline of 1.8% from the prior-year quarter. Next, we'll examine the breakdown of STE's revenue from abroad to comprehend the significance of its international presence.

A Closer Look at STE's Revenue Streams Abroad

Ireland generated $24.12 million in revenues for the company in the last quarter, constituting 1.76% of the total. This represented a surprise of -17.04% compared to the $29.07 million projected by Wall Street analysts. Comparatively, in the previous quarter, Ireland accounted for $22.8 million (1.72%), and in the year-ago quarter, it contributed $19.65 million (1.41%) to the total revenue.

During the quarter, Other Foreign Revenues contributed $343.87 million in revenue, making up 25.09% of the total revenue. When compared to the consensus estimate of $382.04 million, this meant a surprise of -9.99%. Looking back, Other Foreign Revenues contributed $326.58 million, or 24.58%, in the previous quarter, and $350.54 million, or 25.12%, in the same quarter of the previous year.

Projected Revenues in Foreign Markets

Wall Street analysts expect Steris to report a total revenue of $1.49 billion in the current fiscal quarter, which suggests an increase of 5.1% from the prior-year quarter. Revenue shares from Ireland and Other Foreign Revenues are predicted to be 1.9% and 27.9%, corresponding to amounts of $28.25 million and $416.55 million, respectively.

For the entire year, the company's total revenue is forecasted to be $5.48 billion, which is an improvement of 0.7% from the previous year. The revenue contributions from different regions are expected as follows: Ireland will contribute 1.9% ($102.31 million) and Other Foreign Revenues 26.2% ($1.44 billion) to the total revenue.

Wrapping Up

Steris' leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.

Currently, Steris holds a Zacks Rank #3 (Hold), signifying its potential to match the overall market's performance in the forthcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Steris' Recent Stock Market Performance

The stock has witnessed an increase of 8.5% over the past month versus the Zacks S&P 500 composite's an increase of 2.1%. In the same interval, the Zacks Medical sector, to which Steris belongs, has registered an increase of 4.1%. Over the past three months, the company's shares saw an increase of 1.4%, while the S&P 500 increased by 1.2%. In comparison, the sector experienced a decline of 4.2% during this timeframe.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

STERIS plc (STE) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Terms and Privacy Policy

Your Privacy Choices

Utah Privacy Notice

More Info